Development of casein micellar pediatric formulations by Brachkova, M. I. et al.
 - 1 - 
Development of casein micellar pediatric formulations 
 
Mariya Brachkova1, Joana T. Pinto1, Ana I. Fernandes1, João F. Pinto2 
1
 CiiEM,
 
Instituto Superior de Ciências da Saúde Egas Moniz, Campus Universitário, Quinta da 
Granja, Monte de Caparica, 2829-511 Caparica, Portugal, aifernandes@egasmoniz.edu.pt;  
2 
iMed.ULisboa, Faculdade de Farmácia, Universidade de Lisboa, Avenida Professor Gama Pinto 
1649-003 Lisboa, jfpinto@ff.ul.pt; 
 
 
 
INTRODUCTION 
The current need for medicines specifically designed for 
children has driven the development of pediatric drug 
formulations. Important issues to consider are the ease of 
administration, dose flexibility, palatability, safety of 
excipients, stability and therapeutic equivalency of pediatric 
dosage forms (1). 
In the present work casein (CN) based micellar 
formulations are considered attractive vehicles for the oral 
delivery of pediatric drugs, since caseins are nontoxic, 
biodegradable, GRAS (generally regarded as safe) materials 
and nanoencapsulation of drugs can improve their 
bioavailability. Chemical crosslinking of casein by 
carbodiimide (EDC) has been studied as an approach to 
improve the stability of the CN micelles and to tailor drug 
release. EDC was chosen because it induces cross-linking 
of biomaterials, without incorporation in the linkages, 
simply changing to water-soluble urea derivatives, which 
exhibit very low cytotoxicity (2).  
This work aimed to study casein micelles as potential 
pediatric drug vehicles and, also, evaluate the effect of 
crosslinking and processing conditions (freeze-drying) on 
the casein micellar formulation. 
MATERIALS AND METHODS  
Casein dispersions (5mg/ml) were produced by casein 
solubilization with NaOH (1M) at room temperature under 
stirring (500 rpm) and then the pH was adjusted with HCl 
(1M) to 6.5, the natural pH of milk. Paracetamol (PC), one 
of the most widely used drugs in pediatrics, was the model 
drug. PC and/or crosslinker (EDC, 0.03M, during 24h) were 
added to casein dispersions. The dispersions obtained were 
freeze (-80ºC/24h)-dried (-50ºC, 0.035 mbar for 12h) and 
stored at room temperature over silicagel until further use. 
The characterization of casein micellar formulations, before 
and after freeze-drying (FD), was done in triplicate. 
Micelles were characterized for shape by transmission 
electron microscopy, particle size and zeta potential. FTIR 
spectra (4000–400cm−1) and their second derivatives were 
collected and thermograms from DSC analysis (15-200ºC) 
obtained. PC was quantified by HPLC using C18 5 µm 
column and phosphate buffer (0.01M NaH2PO4 pH 5.8) to 
acetonitrile gradient. Free (non-micellar) PC was 
determined in the filtrate, after removal of micelles by 
filtration (Vivaspin 500, 10 kDa cut off) and centrifugation 
at 8000 rpm. Bound (micellar) PC (i.e. encapsulation 
efficiency, EE) was calculated according to the formula: 
𝐸𝐸 (𝐵𝑜𝑢𝑛𝑑 𝑃𝐶, %) =
𝑇𝑜𝑡𝑎𝑙 𝑃𝐶 − 𝐹𝑟𝑒𝑒 𝑃𝐶
𝑇𝑜𝑡𝑎𝑙 𝑃𝐶
 × 100 
The release of PC from uncrosslinked and EDC-
crosslinked micelles was compared in phosphate buffered 
saline (PBS) pH 7.4. Pure PC (control) and PC loaded 
casein micelles were placed into a dialysis membrane (cut 
off 12kDa) suspended into 100mL of PBS pH 7.4, at 37ºC, 
under stirring (100 rpm). Samples were taken at time 
intervals. 
RESULTS AND DISCUSSION 
Microscopic images showed particles (Fig. 1) with 
round shape. 
 
Figure 1. Transmission electron microscopy of casein micelles. 
Size analysis showed that the micellar population in the 
control casein samples, accounted for approximately 60% 
of the casein molecules, (mean size = 178±22 nm). The rest 
of the casein molecules were found either in the monomeric 
form or assembled in larger agglomerates (data not shown). 
When PC was added to casein, a bimodal distribution was 
observed (d = 55±9 nm [60%] and d= 330±70 nm [30%]). 
The addition of the crosslinker resulted in the formation of 
small micelles (80±13 nm) which increased to 106±21 nm 
in the presence of PC. Drug loading may result in some 
micellar size increase due to expansion of the micelle core 
(3). 
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Figure 2.  Second derivative amide I, II and III spectra of crosslinked and uncrosslinked casein. 
 
The process of FD appeared to enhance the micellar size 
homogeneity in all casein formulations increasing the 
micellar populations to over 80-90% (data not shown). 
Negative surface charge (-5 to – 8 mV) was verified for all 
the formulations produced and did not change significantly 
during FD. The fact that micelles maintained their size and 
charge, with just minor changes, is an indicator for 
adequate production conditions. The encapsulation 
efficiency of PC in casein dispersions was approximately 
30% and remained stable during FD in uncrosslinked 
casein, but dropped down to 20% in FD EDC-casein 
samples. 
Casein (uncrosslinked and crosslinked) failed to show a 
thermal event in the temperature range considered (DSC 
study) (data not shown). Interestingly, PC was not 
detectable in the casein-micelles , as the typical melting 
endotherm of paracetamol (polymorph form I) at 
approximately 169ºC was absent, suggesting that PC 
existed in the micelles in the amorphous state or was 
dissolved. FTIR bands of PC in casein micelles 
(uncrosslinked and crosslinked) were predominantly 
invisible due to interference with the casein bands. The 
second derivative spectra of EDC-CN displayed altered 
stretching frequencies and peak shifts, compared to 
uncrosslinked CN, in the amide II region: 1564-1550 cm
-1
 
and amide III region: 1284-1278 cm
-1
, 1273-1255 cm
-1
, 
which could be attributed to potential intramolecular cross-
linking (Fig. 2). 
The release of PC from casein micelles in PBS, pH 7.4, 
at 37ºC, is shown in Fig. 3. A burst effect was observed for 
the PC unbound into the casein micelles: the unbound PC 
was released at a similar rate as the control pure drug 
(p>0.7). However, significantly retarded release was found 
for the PC entrapped into the casein micelles as compared 
to the free drug control (p<0.0001). The use of crosslinker 
further retarded the release of the drug. The bound 
(approximately 20%) into the EDC-crosslinked micelles PC 
was released at a significantly lower rate compared to that 
bound into uncrosslinked casein micelles drug (p<0.01). 
 
 
Figure 3. Release of paracetamol (%) in PBS, pH 7.4 at 37ºC, 
from FD casein micelles 
 
CONCLUSION 
The study suggests that casein could be a vehicle for the 
delivery of drugs in pediatrics, permitting a straightforward 
production process with minimal number of non-toxic 
excipients. The study also provides information on the use 
of carbodiimide as a crosslinker for the production of 
stabilized casein micelles with retarded release of the 
encapsulated drug that would reduce dosing frequency. 
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